Frank Stenner

University of Basel — Switzerland

Medicine · Health Sciences

33h-index4.9kcitations201works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(37), CAR-T cell therapy research(29), Prostate Cancer Treatment and Research(26), Cancer Immunotherapy and Biomarkers(24), Bladder and Urothelial Cancer Treatments(16)

Publications200 total

Multi-omic profiling reveals key drivers of response to dual CTLA-4/PD-1 immunotherapy in mRCC 4681
The Journal of Immunology·2025Open Access
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Annals of Oncology·2025· 5 cited
A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma
2025Open Access
Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma
2025Open Access
CAR T cell engineering impacts antigen-independent activation and co-inhibition
Molecular Therapy — Methods & Clinical Development·2025Open Access
3107P Intravesical recombinant BCG followed by perioperative chemo-immunotherapy (chemo-IO) for patients with muscle-invasive bladder cancer (MIBC): Interim analysis of SAKK 06/19 study
Annals of Oncology·2025
ABCL-1118: Durability of Complete Responses in Patients From the ECHELON-3 Study
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-1118 Durability of Complete Responses in Patients From the ECHELON-3 Study
Clinical Lymphoma Myeloma & Leukemia·2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
Nature Medicine·2025· 2 cited
Interdisciplinary Swiss Consensus Recommendations on Management of Advanced Prostate Cancer.
PubMed·2025
PDL1-expressing macrophages infiltrate diffuse large B-cell lymphoma and promote lymphoma growth in a MYC-driven experimental model
Blood Cancer Journal·2025· 1 citedOpen Access
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study
Blood Advances·2025· 7 citedOpen Access
Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.
Journal of Clinical Oncology·2025· 3 cited
Distinct subtypes of post‐transplant lymphoproliferative disorders: <scp>CHIP</scp>‐like mutations in early lesions and substantial mutational differences between <scp>EBV</scp>‐positive and <scp>EBV</scp>‐negative diffuse large B‐cell lymphomas
British Journal of Haematology·2025· 2 citedOpen Access
Durability of Complete Responses in Patients from the ECHELON-3 Study
Blood·2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Journal of Clinical Oncology·2024· 85 citedOpen Access
Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive <scp>B‐</scp>cell lymphoma: Insights from real‐life clinical practice
Cancer Reports·2024· 2 citedOpen Access
Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies
Swiss Medical Weekly·2024Open Access
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?
Leukemia & lymphoma/Leukemia and lymphoma·2024Open Access
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma
Immuno-Oncology Technology·2024· 8 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Christoph Renner(15), Heike Liewen(12), Panagiotis Samaras(12), Alexander Knuth(12), Alfred Zippelius(6), John C. Reed(6), Michael Pfreundschuh(4), Michal A. Stanczak(4), Heinz Läubli(4), Stefan Bauer(4), Andreas Wadle(4), Urs Schanz(4), Richard Cathomas(4), Martin Zweifel(4), Uğur Şahin(3), Guorong Luo(3), Sascha Kleber(3), Bernhard C. Pestalozzi(3), Beat Müllhaupt(3), Peter J. Wild(3)